Secondary CD5+Diffuse Large B-Cell Lymphoma Not Associated With Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Richter Syndrome)

被引：13
作者：
Maeshima, Akiko Miyagi [1 ]
Taniguchi, Hirokazu
Nomoto, Junko [2 ]
Maruyama, Dai [2 ]
Kim, Sung-Won [2 ]
Watanabe, Takashi [2 ]
Kobayashi, Yukio [2 ]
Tobinai, Kensei [2 ]
Matsuno, Yoshihiro [3 ]
机构：
[1] Natl Canc Ctr, Clin Lab Div, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Hematol & Stem Cell Transplantat Div, Tokyo 1040045, Japan
[3] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 060, Japan
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2009年 / 131卷 / 03期
关键词：
CD5; Diffuse large B-cell lymphoma; Secondary disease; Immunohistochemistry; Non-Richter syndrome; FOLLICULAR LYMPHOMA; CD5+;
D O I：
10.1309/AJCP58FETFGLCKKW
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Few cases of secondary CD5+ diffuse large B-cell lymphoma (DLBCL) that are not Richter syndrome have been reported previously. We report 9 cases of non-Richter syndrome secondary CD5+ DLBCL. Among 529 cases of DLBCL, 38 (7.2%) were CD5+ DLBCL, including 9 of secondary CD5+ DLBCL. Five cases gained CD5 expression during the clinical course of DLBCL (group 1). Three cases showed transformation from CD5-low-grade B-cell lymphoma to CD5+ DLBCL (group 2). The remaining case showed coexistence of CD5+ DLBCL and CD5+ follicular lymphoma. The clonal relationships of CD5- and CD5+ tumors were confirmed in all 4 available cases. Cases of secondary CD5+ DLBCL that were not Richter syndrome were classifiable into 3 groups. Groups I and 2 showed the gain of CD5 during the clinical course or transformation of the tumors, suggesting that CD5 expression is closely associated with the progression of B-cell lymphoma.
引用
收藏
页码：339 / 346
页数：8
相关论文
共 21 条
  • [1] CD5+ low-grade marginal zone B-cell lymphomas with localized presentation
    Ballesteros, E
    Osborne, BM
    Matsushima, AY
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (02) : 201 - 207
  • [2] Barekman CL, 2001, ARCH PATHOL LAB MED, V125, P951
  • [3] Barry TS, 2002, AM J CLIN PATHOL, V118, P589
  • [4] Catherwood MA, 2006, AM J CLIN PATHOL, V125, P954
  • [5] Ferry JA, 1996, AM J CLIN PATHOL, V105, P31
  • [6] CD5+ diffuse large B-cell lymphoma with c-myc/IgH rearrangement presenting as primary effusion lymphoma
    Fujisawa, S
    Tanioka, F
    Matsuoka, T
    Ozawa, T
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (04) : 315 - 318
  • [7] The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities
    Fujita, M
    Yamashiro, K
    Ichinohasama, R
    Nakamura, N
    Abe, M
    Wakasa, H
    Kojima, M
    Motoori, T
    Izumo, T
    Tamaru, J
    Mikata, A
    Takeuchi, K
    Kakiuchi, C
    Mori, S
    Matsuno, Y
    Nakamura, S
    Yatabe, Y
    Ichimura, K
    Suchi, T
    Tajima, K
    Mori, N
    Takasaki, K
    Tsurumi, K
    Takami, T
    Haga, H
    Sakurai, T
    Yamabe, H
    Kobashi, Y
    Ohsawa, M
    Kanno, H
    Aozasa, K
    Nakamine, H
    Yoshino, T
    Akagi, T
    Sasaki, N
    Namba, K
    Agatsuma, Y
    Iwata, K
    Suzumiya, J
    Ohshima, K
    Kikuchi, M
    Takeshita, M
    Hasui, K
    Sato, E
    Sueyoshi, K
    Tokunaga, M
    [J]. PATHOLOGY INTERNATIONAL, 2000, 50 (09) : 696 - 702
  • [8] Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    Hans, CP
    Weisenburger, DD
    Greiner, TC
    Gascoyne, RD
    Delabie, J
    Ott, G
    Müller-Hermelink, HK
    Campo, E
    Braziel, RM
    Jaffe, ES
    Pan, ZG
    Farinha, P
    Smith, LM
    Falini, B
    Banham, AH
    Rosenwald, A
    Staudt, LM
    Connors, JM
    Armitage, JO
    Chan, WC
    [J]. BLOOD, 2004, 103 (01) : 275 - 282
  • [9] Harris N.L., 2001, NEOPLASTIC HEMATOPAT, P823
  • [10] THE CD5 B-CELL
    KIPPS, TJ
    [J]. ADVANCES IN IMMUNOLOGY, 1989, 47 : 117 - +
123